Liver disease is next target for obesity drugs in development

Drugmakers are eyeing GLP-1 drugs as a possible treatment for the liver disease MASH, a growing, multibillion-dollar market.

February 26, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Liver disease MASH is next target for obesity drugs in development Wegovy and Zepbound have spurred drug companies to study obesity treatments in the increasingly common liver disease MASH. By Elaine Chen STAT+ | Congress punts on PBM reform efforts Congress has abandoned its attempt to reform how PBMs operate in an upcoming package to fund the federal government, 11 sources said. By Rachel Cohrs and John Wilkerson STAT+ | Private equity firm offers $5.8 billion buyout of hospital billing company R1 RCM Private equity firm New Mountain Capital has offered to purchase R1 RCM, a health care collections vendor, for roughly $5.8 billion in cash. By Bob Herman Dave Martin/AP Opinion: A new Louisiana capital-punishment bill would fundamentally alter physician licensing Louisiana's bill legalizing capital punishment by nitrogen gas would effectively wrest control of physician conduct from medical boards. By Joel B. Zivot STAT+ | Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH The drug, called survodutide and developed by Boehringer Ingelheim and Zealand Pharma, is also in Phase 3 trials for obesity. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser